Part A - Interim decisions on matters referred to an expert advisory committee (November 2017)

Scheduling medicines and poisons

Last updated

5 February 2018

Advisory Committee on Medicines Scheduling (ACMS #22)

Summary of delegate's final decisions
Substance	Interim Decision
Hyaluronic acid	Schedule 4 - Amend Entry HYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation. The proposed implementation date is 1 June 2018.
Cardarine	Schedule 10 - New Entry CARDARINE. Index – New Entry CARDARINE Schedule 10 The proposed implementation date is 1 June 2018.
Stenabolic (SR9009)	Schedule 4 - New Entry # STENABOLIC (SR9009) and other synthetic REV-ERB agonists. Appendix D, Part 5 - New Entry STENABOLIC (SR9009) and other synthetic REV-ERB agonists. Index – New Entry STENABOLIC (SR9009) and other synthetic REV-ERB agonists cross reference: SR9011, GSK2945, GSK0999, GSK5072, GSK2667 Schedule 4 Appendix D, Part 5 The proposed implementation date is 1 June 2018.
Ibutamoren	Schedule 4 - New Entry # IBUTAMOREN. Appendix D, Part 5 – New Entry IBUTAMOREN. Index – New Entry IBUTAMOREN cross reference: MK-677, NUTROBAL Schedule 4 Appendix D, Part 5 The proposed implementation date is 1 June 2018.
alpha-Pyrrolidinovalerophenone (alpha-PVP) and related substances methylone and synthetic cathinones	Schedule 9 - New Entry ALPHA-PYRROLIDINOVALEROPHENONE (ALPHA-PVP). Schedule 9 - New Entry METHYLONE (MDMC). Schedule 9 - Amend Entry CATHINONES except when separately specified in these Schedules. Index - Amend Entry CATHINONES cross reference: SYNTHETIC CATHINONES The proposed implementation date is 1 June 2018.
Ibuprofen	The delegate’s interim decision is that the current scheduling of ibuprofen remains appropriate
Melanotan II	Schedule 4 - New Entry MELANOTAN II. Index - New Entry MELANOTAN II cross reference: α–MELANOCYTE STIMULATING HORMONE Schedule 4 The proposed implementation date is 1 June 2018.
Orphenadrine	The delegate’s interim decision is that the current scheduling of ibuprofen remains appropriate.
Clotrimazole	The delegate’s interim decision is that the current scheduling of ibuprofen remains appropriate.